摘要
This work presents the synthesis and characterization of compounds derived from the ruthenium transition metal with the nitrogenous ligand 4-aminopy- ridine (4-ampy). The synthesized compounds were characterized by FTIRmed spectroscopy and TG-DTA thermal analysis. For the cytotoxic evaluation of ruthenium compounds, a 66.0 μM aqueous solution containing the complex and the study of data observed in the biological assessment was performed using variance (ANOVA) analysis, followed by Tukey’s multiple comparisons test. Differences between treatments were considered significant when the p-value was less than 0.05 (p < 0.05). TG/DSC thermal analysis for the first complex suggests a stoichiometry of [Ru(Cl)<sub>3</sub>(4-ampy)(H<sub>2</sub>O)<sub>2</sub>]·1/2H<sub>2</sub>O, which, due to the low solubility in an aqueous medium, was modified to increase its solubility for biological tests. The analysis of the spectra in the medium infrared region (FTIR) for the complex [Ru(Cl)<sub>3</sub>(4-ampy)(H<sub>2</sub>O)<sub>2</sub>]·1/2H<sub>2</sub>O, shows displacements of the bands observed at 1625 - 1566 cm<sup>﹣1</sup> ν(C=C) e (C=N), indicating that coordination to the metallic center occurred by this group. Band displacements were observed in the modified Ru (III) complex, which suggests the presence of the 4-ampy ligand and the coordination by the groups ν(C=C) and (C=N) after the modification. In recent years, researchers worldwide have concentrated on obtaining, developing, and modifying drugs used as chemotherapeutic agents. The evaluation of the cell viability of the modified Ru (III) compound demonstrated cytotoxic effects in the MCF-7 cell line (15.33% ± DP 2.7) but did not affect normal cells (PBMC), which reflects the potential for possible applications.
This work presents the synthesis and characterization of compounds derived from the ruthenium transition metal with the nitrogenous ligand 4-aminopy- ridine (4-ampy). The synthesized compounds were characterized by FTIRmed spectroscopy and TG-DTA thermal analysis. For the cytotoxic evaluation of ruthenium compounds, a 66.0 μM aqueous solution containing the complex and the study of data observed in the biological assessment was performed using variance (ANOVA) analysis, followed by Tukey’s multiple comparisons test. Differences between treatments were considered significant when the p-value was less than 0.05 (p < 0.05). TG/DSC thermal analysis for the first complex suggests a stoichiometry of [Ru(Cl)<sub>3</sub>(4-ampy)(H<sub>2</sub>O)<sub>2</sub>]·1/2H<sub>2</sub>O, which, due to the low solubility in an aqueous medium, was modified to increase its solubility for biological tests. The analysis of the spectra in the medium infrared region (FTIR) for the complex [Ru(Cl)<sub>3</sub>(4-ampy)(H<sub>2</sub>O)<sub>2</sub>]·1/2H<sub>2</sub>O, shows displacements of the bands observed at 1625 - 1566 cm<sup>﹣1</sup> ν(C=C) e (C=N), indicating that coordination to the metallic center occurred by this group. Band displacements were observed in the modified Ru (III) complex, which suggests the presence of the 4-ampy ligand and the coordination by the groups ν(C=C) and (C=N) after the modification. In recent years, researchers worldwide have concentrated on obtaining, developing, and modifying drugs used as chemotherapeutic agents. The evaluation of the cell viability of the modified Ru (III) compound demonstrated cytotoxic effects in the MCF-7 cell line (15.33% ± DP 2.7) but did not affect normal cells (PBMC), which reflects the potential for possible applications.
